Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
HCC3153
TNBC
Basal A
Ibandronate
FDPS
10937.143
uM
76.74170
86.08140
-0.1089 -0.1059 1.6725 0.2383
0.9923
1.3133
HCC3153
TNBC
Basal A
ICRF-193
TOP2
TOP
10577.139
uM
inf
inf
0.7835 0.7835 0.0000 0.0451
0.2207
0.9234
HCC3153
TNBC
Basal A
ICRF-193
TOP2
TOP
10937.151
uM
inf
0.18074
0.6444 0.6849 3.1243 0.1468
0.8890
1.5219
HCC3153
TNBC
Basal A
IKK16
IKK
NFKB
7465.1
uM
2.88150
3.99290
-0.9646 -0.9784 3.3234 0.4962
0.980
1.2603
HCC3153
TNBC
Basal A
IKK16
IKK
NFKB
10577.1
uM
9.01030
11.20710
-0.9879 -0.9882 4.9993 0.2835
0.9980
0.8774
HCC3153
TNBC
Basal A
IKK16
IKK
NFKB
7466.093
uM
2.9670
3.71370
-0.9887 -0.9902 4.8649 0.4266
0.9987
0.8543
HCC3153
TNBC
Basal A
Imatinib
ABL/KIT/PDGFR
nRTK
7465.092
uM
27.12530
44.23040
-0.9769 -0.9968 2.2426 0.5071
0.9579
1.2055
HCC3153
TNBC
Basal A
Imatinib
ABL/KIT/PDGFR
nRTK
7467.091
uM
27.82050
39.93920
-0.9764 -0.9798 3.0007 0.4263
0.9973
1.2996
HCC3153
TNBC
Basal A
Imatinib
ABL/KIT/PDGFR
nRTK
7466.092
uM
30.23740
41.10640
-0.9899 -0.9905 3.5568 0.4036
0.9988
0.9158
HCC3153
TNBC
Basal A
Ispinesib
KSP
Kinesin
7467.067
uM
0.02071
0.02955
-0.9735 -0.4581 1.8299 0.7674
0.9122
1.3252
HCC3153
TNBC
Basal A
Ispinesib
KSP
Kinesin
7466.067
uM
0.03319
0.03912
-0.9891 -0.6378 4.9994 0.8533
0.9713
0.9457
HCC3153
TNBC
Basal A
Ixabepilone
TUBB
TUBB
7465.095
uM
0.00639
0.01097
-0.9474 -0.4667 1.2203 0.9133
0.8917
1.2754
HCC3153
TNBC
Basal A
Ixabepilone
TUBB
TUBB
7467.095
uM
0.0040
0.00623
-0.9545 -0.5226 1.6137 1.0115
0.9385
1.2671
HCC3153
TNBC
Basal A
Ixabepilone
TUBB
TUBB
7466.095
uM
0.01109
0.01588
-0.9919 -0.6670 2.3641 0.9758
0.9686
0.8699
HCC3153
TNBC
Basal A
JNK-IN-5A
JNK
JNK
10937.144
uM
2.08580
1.59690
0.5745 0.3685 5.0000 0.2219
0.6796
1.5466
HCC3153
TNBC
Basal A
JNK-IN-5A
JNK
JNK
10577.144
uM
1.51110
1.66060
-0.2905 -0.3013 5.0000 0.4344
0.9877
0.9534
HCC3153
TNBC
Basal A
L-779450
BRAF
MAPK
10577.137
uM
128.91780
407.61850
0.8182 -0.9196 0.9065 0.0143
0.7373
0.9653
HCC3153
TNBC
Basal A
L-779450
BRAF
MAPK
10937.149
uM
45.2220
35.9980
0.7333 0.3402 4.9999 -0.0142
0.8321
1.3519
HCC3153
TNBC
Basal A
Lapatinib
EGFR/HER2
ErbB
7467.098
uM
inf
inf
0.9507 0.9507 0.0000 -0.0070
0.1810
1.4178
HCC3153
TNBC
Basal A
Lapatinib
EGFR/HER2
ErbB
7465.098
uM
inf
inf
0.7421 0.7421 0.0000 0.1459
0.2598
1.2188
HCC3153
TNBC
Basal A
Lapatinib
EGFR/HER2
ErbB
7466.098
uM
inf
inf
0.6772 0.6772 0.0000 0.0999
0.3464
0.8226
HCC3153
TNBC
Basal A
LBH589
HDAC
HDAC
10937.154
uM
0.29675
0.44798
-0.5527 -0.5092 1.7053 0.5085
0.9958
1.5291
HCC3153
TNBC
Basal A
Lestaurtinib
FLT3/JAK2/TrkA
RTK
10577.142
uM
6.5240
9.92430
-0.9691 -0.9764 2.5810 0.4740
0.9587
1.0584
HCC3153
TNBC
Basal A
Lestaurtinib
FLT3/JAK2/TrkA
RTK
10937.154
uM
7.62070
11.29650
-0.9117 -1.0000 2.7910 0.2041
0.9933
1.5291
HCC3153
TNBC
Basal A
Mebendazole
13733.174
uM
0.22612
8.73650
-0.5068 -1.0000 0.3006 0.5298
0.8956
0.5093